<DOC>
	<DOCNO>NCT01445678</DOCNO>
	<brief_summary>This Phase 3 , multicenter , prospective , randomize , double-blind , double dummy study CXA-201 Intravenous ( IV ) infusion ( 1500mg q8h ) metronidazole ( 500mg q8h ) versus meropenem ( 1000mg q8h ) treatment adult Complicated Intraabdominal Infections ( cIAI ) .</brief_summary>
	<brief_title>Study Comparing Safety Efficacy Intravenous CXA-201 Intravenous Meropenem Complicated Intraabdominal Infections</brief_title>
	<detailed_description>Approximately , 500 subject enrol study , randomize 1:1 receive CXA-201 metronidazole comparator ( meropenem ) . Subject participation require minimum commitment 38 day maximum 45 day . An End Treatment ( EOT ) visit occur within 24 hour follow last dose study drug administration/drug discontinuation . A Test Cure ( TOC ) /Safety visit conduct 26 30 day follow first dose study drug administration . A Last Follow-up ( LFU ) visit conduct 38 45 day first dose study drug .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>Diagnoses cIAI . Subject require surgical intervention ( e.g. , laparotomy , laparoscopic surgery , percutaneous drain abscess ) within 24 hour ( ) first dose study drug . Simple appendicitis ; acute suppurative cholangitis ; infect necrotizing pancreatitis ; pancreatic abscess ; pelvic infection . Complicated intraabdominal infection manage staged abdominal repair ( STAR ) , open abdomen technique include temporary closure abdomen , situation infection source control likely achieve . Use systemic antibiotic therapy IAI 24 hour prior first dose study drug , unless document treatment failure therapy . Have concomitant infection time randomization , require nonstudy systemic antibacterial therapy addition IV study drug therapy . ( Drugs grampositive activity [ e.g. , daptomycin , vancomycin , linezolid ] allow ) . Severe impairment renal function ( estimate CrCl &lt; 30 mL/min ) , requirement peritoneal dialysis , hemodialysis hemofiltration , oliguria ( &lt; 20 mL/h urine output 24 hour ) . The presence hepatic disease baseline . Considered unlikely survive 4 5 week study period . Any rapidlyprogressing disease immediately lifethreatening illness ( include respiratory failure septic shock ) . Have document history moderate severe hypersensitivity allergic reaction βlactam antibacterial ( history mild rash follow uneventful reexposure contraindication enrollment ) , include cephalosporin , carbapenems , penicillin , ßlactamase inhibitor , metronidazole , nitroimidazole derivative . Women pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>cIAI</keyword>
</DOC>